161 related articles for article (PubMed ID: 26384449)
1. An economic analysis of adult hepatitis B vaccination in China.
Zheng H; Wang FZ; Zhang GM; Cui FQ; Wu ZH; Miao N; Sun XJ; Liang XF; Li L
Vaccine; 2015 Nov; 33(48):6831-9. PubMed ID: 26384449
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of economic outcomes of "hepatitis B vaccine event reported by media" in China, 2013].
Zhang SX; Sun PP; Xia Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Aug; 52(8):837-841. PubMed ID: 30107719
[No Abstract] [Full Text] [Related]
3. [Economic evaluation and prediction of hepatitis B immunization strategy in Shenzhen, China].
Sun PP; Zhang SX; Xia Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jul; 52(7):743-747. PubMed ID: 29996303
[No Abstract] [Full Text] [Related]
4. [Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China].
Zhang SX; Dang RB; Zhang WD; Liang XF; Cui FQ
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Oct; 29(10):1003-8. PubMed ID: 19173882
[TBL] [Abstract][Full Text] [Related]
5. [Cost-benefit analysis of the hepatitis B vaccination to prevent mother-to-child transmission strategies in China, 1992-2019].
Zheng H; Wang FZ; Zhang GM; Miao N; Liang XF; Yin ZD
Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Sep; 42(9):1537-1545. PubMed ID: 34814581
[No Abstract] [Full Text] [Related]
6. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations.
Margolis HS; Coleman PJ; Brown RE; Mast EE; Sheingold SH; Arevalo JA
JAMA; 1995 Oct; 274(15):1201-8. PubMed ID: 7563509
[TBL] [Abstract][Full Text] [Related]
7. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
Hung HF; Chen TH
Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
[TBL] [Abstract][Full Text] [Related]
8. [Economic evaluation on strategy for preventing mother-to-child transmission of hepatitis B in Zhejiang Province].
Zeng YB; Luo ML; He HQ; Deng X; Xie SY; Fang Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Jul; 53(7):706-712. PubMed ID: 31288342
[No Abstract] [Full Text] [Related]
9. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites.
Kim SY; Billah K; Lieu TA; Weinstein MC
Am J Prev Med; 2006 Jun; 30(6):498-506. PubMed ID: 16704944
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B vaccination coverage rates among adults in rural China: are economic barriers relevant?
Zhu D; Wang J; Wangen KR
Vaccine; 2014 Nov; 32(49):6705-10. PubMed ID: 23845801
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of universal newborn hepatitis B vaccination in China.
Lu SQ; McGhee SM; Xie X; Cheng J; Fielding R
Vaccine; 2013 Apr; 31(14):1864-9. PubMed ID: 23384752
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits.
Boccalini S; Taddei C; Ceccherini V; Bechini A; Levi M; Bartolozzi D; Bonanni P
Hum Vaccin Immunother; 2013 May; 9(5):1119-28. PubMed ID: 23376840
[TBL] [Abstract][Full Text] [Related]
14. An economic evaluation of universal vaccination against hepatitis B virus.
Fenn P; Gray A; McGuire A
J Infect; 1996 May; 32(3):197-204. PubMed ID: 8793708
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two vaccination strategies against hepatitis A and B in patients with chronic hepatitis C.
Díez Redondo MP; Almaraz A; Jiménez Rodríguez-Vila M; Santamaría A; de Castro J; Torrego JC; Caro-Patón A
Rev Esp Enferm Dig; 2009 Apr; 101(4):265-74. PubMed ID: 19492902
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
Kuan RK; Janssen R; Heyward W; Bennett S; Nordyke R
Vaccine; 2013 Aug; 31(37):4024-32. PubMed ID: 23707166
[TBL] [Abstract][Full Text] [Related]
17. [Cost-benefit analysis of vaccinal prevention of hepatitis B policy].
Kerleau M; Flori YA; Nalpas B; Lanoé JL; Berthelot P; Fardeau-Gautier M
Rev Epidemiol Sante Publique; 1995; 43(1):48-60. PubMed ID: 7892516
[TBL] [Abstract][Full Text] [Related]
18. Preventing Hepatitis B Virus Infection Among U.S. Military Personnel: Potential Impact of a 2-Dose Versus 3-Dose Vaccine on Medical Readiness.
Oelschlager KA; Termini MS; Stevenson C
Mil Med; 2023 Jul; 188(7-8):e2067-e2073. PubMed ID: 36525511
[TBL] [Abstract][Full Text] [Related]
19. Key outcomes and addressing remaining challenges--perspectives from a final evaluation of the China GAVI project.
Yang W; Liang X; Cui F; Li L; Hadler SC; Hutin YJ; Kane M; Wang Y
Vaccine; 2013 Dec; 31 Suppl 9():J73-8. PubMed ID: 24331024
[TBL] [Abstract][Full Text] [Related]
20. The cost effectiveness of hepatitis immunization for US college students.
Jacobs RJ; Saab S; Meyerhoff AS
J Am Coll Health; 2003 May; 51(6):227-36. PubMed ID: 14510025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
